Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis

Human Pathology

Volumn 37, Issue 10, 2006, Pages 1279-1285

  Chen, Chi Long ^a,b   Ou, Da Liang ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Epstein Barr virus; Nasopharyngeal carcinoma; Syndecan 1

Indexed keywords

LATENT MEMBRANE PROTEIN 1; SYNDECAN 1;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

CARCINOMA; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE GLYCOPROTEINS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SYNDECAN-1; SYNDECANS; TUMOR MARKERS, BIOLOGICAL; VIRAL MATRIX PROTEINS;

EID: 33748620660     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.04.024     Document Type: Article

References (35)

1. Hsu M.M., and Tu S.M. Nasopharyngeal carcinoma in Taiwan: clinical manifestations and results of therapy. Cancer 52 (1983) 362-368
2. Teo P.M., Kwan W.H., Lee W.Y., Leung S.F., and Johnson P.J. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 77 (1996) 2423-2431
3. Kieff E., and Rickinson A.B. Epstein-Barr virus and its replication. In: Fields B.N., Howley P.M., Griffin D.E., et al. (Eds). Field's virology. 4th ed. vol. 2 (2001), Lippincott, Williams and Wilkins Publishers, Philadelphia 2511-2573
4. Miller W.E., Cheshire J.L., Baldwin Jr. A.S., and Raab-Traub N. The NPC derived C15 LMP1 protein confers enhanced activation of NF-kappa B and induction of the EGFR in epithelial cells. Oncogene 16 (1998) 1869-1877
5. Horikawa T., Yoshizaki T., Sheen T.S., Lee S.Y., and Furukawa M. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 89 (2000) 715-723
6. Yoshizaki T. Promotion of metastasis in nasopharyngeal carcinoma by Epstein-Barr virus latent membrane protein-1. Histol Histopathol 17 (2002) 845-850
7. Engers R., and Gabbert H.E. Mechanisms of tumor metastasis: cell biological aspects and clinical implications. J Cancer Res Clin Oncol 126 (2000) 682-692
8. Stetler-Stevenson W.G., and Kleiner Jr. D.E. Molecular biology of cancer: invasion and metastases. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 6th ed. (2001), Lippincott Williams and Willkins, Philadelphia 123-136
9. Sun X., Mosher D.F., and Rapreager A. Heparan sulfate-mediated binding of epithelial cell surface proteoglycan to thrombospondin. J Biol Chem 264 (1989) 2885-2889
10. Bernfield M., Kokenyesi R., Kato M., et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 8 (1992) 365-393
11. Carey D.J. Syndecans: multifunctional cell-surface co-receptors. Biochem J 327 (1997) 1-16
12. Sanderson R.D., Hinkes M., and Bernfield M. Syndecan-1, a cell surface proteoglycan, changes in size and abundance when keratinocytes stratify. J Invest Dermatol 99 (1992) 390-396
13. Vainio S., Jalkanen M., Bernfield M., and Saxen L. Transient expression of syndecan in mesenchymal cell aggregates of the embryonic kidney. Dev Biol 152 (1992) 221-232
14. Koda J., Rapraeger A., and Bernfield M. Heparan sulfate proteoglycans from mouse mammary epithelial cells: cell surface proteoglycan as a receptor for interstitial collagens. J Biol Chem 260 (1985) 8157-8162
15. Elenius K., Salmivirta M., Inki P., Mali M., and Jalkanen M. Binding of human syndecan to extracellular matrix proteins. J Biol Chem 265 (1990) 17837-17843
16. Kato M., Saunders S., Nguyen H., and Nernfield M. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 6 (1995) 559-576
17. Kiviniemi J., Kallajoki M., Kujala I., et al. Altered expression of syndecan-1 in prostate cancer. APMIS 112 (2004) 89-97
18. Mukunyadzi P., Liu K., Hanna E.T., Suen J.Y., and Fan C.Y. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma. Mod Pathol 16 (2003) 796-801
19. Barbareschi M., Maisonneuve P., Aldovini D., et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98 (2003) 474-483
20. Chan J.K.C., Bary F., McCarron P., et al. Nasopharyngeal Carcinoma. In: Barnes L., Eveson J.W., Reichart P., and Sidransky D. (Eds). Pathology and genetics of head and neck tumours. WHO classification of tumours (2005), IARC Press, Lyon 85-97
21. In: Sobin L.H., and Wittekind C.H. (Eds). UICC TNM classification of malignant tumors. 5th ed (1997), Springer-Verlag, Berlin 27-30
22. Olsson U., Egnell A.C., Lee M.R., et al. Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic cells may contributes to dyslipidemia of insulin resistance. Diabetes 50 (2001) 2126-2132
23. Anttonen A., Kajanti M., Heikkila P., Jalkanen M., and Joensuu H. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 79 (1999) 447-455
24. Mikami S., Ohashi K., Usui Y., et al. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res 92 (2001) 1062-1073
25. Pulkkinen J.O., Penttinen M., Jalkanen M., Klemi P., and Grenman R. Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol 117 (1997) 312-315
26. Matsumoto A., Ono M., Fujimoto Y., Gallo R.L., Bernfield M., and Kohgo Y. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 74 (1997) 482-491
27. Anttonen A., Heikkila P., Kajanti M., Jalkanen M., and Joensuu H. High syndecan-1 expression is associated with favorable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 32 (2001) 297-305
28. Fujiya M., Watari J., Ashida T., et al. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 92 (2001) 1074-1081
29. Numa F., Hirabayashi K., Kawasaki K., et al. Syndecan-1 expression in cancer of the uterine cervix: association with lymph node metastasis. Int J Oncol 20 (2002) 39-43
30. Zellweger T., Ninck C., Mirlacher M., et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 55 (2003) 20-29
31. Ito Y., Yoshida H., Nakano K., et al. Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 43 (2003) 157-164
32. Hsu H.C., Chen C.L., Hsu M.M., Lynn T.C., Tu S.M., and Huang S.C. Pathology of nasopharyngeal carcinoma: proposal of a new histological classification correlated with prognosis. Cancer 59 (1987) 945-951
33. Maeda T., Alexander C.M., and Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res 64 (2004) 612-621
34. Mennerich D., Vogel A., Klaman L., et al. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumors. Eur J Cancer 40 (2004) 1373-1382
35. Ren Q., Sato H., Murono S., Furukawa M., and Yoshizaki T. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line. Laryngoscope 114 (2004) 855-859